Factors associated with therapeutic response to adalimumab in hidradenitis suppurativa: evidence from the Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be).

Abstract excerpt

Hidradenitis suppurativa is an inflammatory skin disease for which adalimumab is an effective treatment in just over half of cases. Few factors associated with therapeutic response, and therefore potentially predictive of response, are known to date. This real-life study retrospectively explores the existence of such factors in a Belgian cohort of 82 patients, using several response scores: the Hidradenitis...

Topics

Join the communities discussing this publication.

• Adalimumab
• Anti-Inflammatory Agents
• Belgium
• Hidradenitis Suppurativa